FDA Approves Adrabetadex as First Therapy to Prolong Survival in Infantile-Onset Niemann-Pick Type C
The FDA has approved adrabetadex to treat infantile-onset Niemann-Pick disease type C, marking the first therapy shown to extend survival for the severe neurodegenerative disorder. The intrathecal injection reduced the risk of death by 55 percent in clinical studies, though it carries a boxed warning for permanent hearing loss.
Share this story
The U.S. Food and Drug Administration approved adrabetadex on November 17, 2026, establishing the first therapy shown to prolong survival in patients with infantile-onset Niemann-Pick disease type C. Marketed as Lembaz by Beren Therapeutics, the injection targets the cellular defect that drives the severe neurodegenerative disorder.[1][4]
The regulatory clearance covers adult and pediatric patients weighing at least 7 kilograms whose neurological symptoms began before six years of age. Infantile-onset cases represent the most rapidly progressive form of the disease, typically leading to early mortality without targeted intervention.[1][3]
“Because neurological function that is lost cannot be regained, early diagnosis and prompt treatment are critical,” said Elizabeth M. Berry-Kravis, professor of pediatrics and neurological sciences at Rush University Medical Center. “For the first time, LEMBAZ gives clinicians a way to address the underlying cholesterol trafficking defect.”[3]
Reversing cellular cholesterol traps
Niemann-Pick disease type C is a rare, autosomal-recessive genetic disorder caused primarily by mutations in the NPC1 or NPC2 genes. These mutations disable the proteins responsible for transporting cholesterol and other lipids out of cellular compartments called lysosomes, causing toxic accumulation.[4][5]
Lysosomes act as the recycling centers of the cell, breaking down complex molecules for reuse. When the NPC1 transport protein fails, unesterified cholesterol and glycolipids accumulate inside these organelles, causing them to engorge and eventually disrupt the cell's structural integrity and metabolic signaling.[4]
In the central nervous system, this lipid storage defect is particularly devastating to Purkinje cells in the cerebellum, which govern motor control. The resulting neuronal death drives the ataxia, dysarthria, and eventual loss of voluntary movement that characterize the disease's clinical progression.[2][4]
Adrabetadex is a proprietary mixture of 2-hydroxypropyl-β-cyclodextrin isomers designed to act as an alternative transport mechanism. By chemically mobilizing the trapped intracellular cholesterol, the therapy compensates for the defective NPC proteins and allows the lipids to be distributed normally for cellular function.[2][5]
Because the cyclodextrin molecule cannot readily cross the blood-brain barrier, it must be administered directly into the cerebrospinal fluid. A trained healthcare provider delivers the medication via an intrathecal injection into the spinal canal once every two weeks.[1][2]
Survival data and external controls
The FDA based its approval on an externally controlled survival analysis rather than a traditional randomized placebo trial, reflecting the ethical and logistical challenges of studying a rare, fatal pediatric disease. Regulators evaluated 36 patients treated with adrabetadex across three clinical studies and an expanded access program.[1][5]
The three clinical studies supporting the application—designated NCT02534844, NCT03643562, and NCT04958642—tracked patients over several years of continuous intrathecal therapy. The expanded access program provided additional real-world survival data, reinforcing the durability of the treatment effect outside of strict trial protocols.[5]
Analysts compared the outcomes of those 36 treated individuals against a matched external control group drawn from natural history data. The agency determined that this comparison constituted an adequate and well-controlled study, demonstrating a clear divergence in disease trajectories.[1][2]
Patients receiving adrabetadex experienced a 55 percent reduction in the risk of death compared to the external controls. The median overall survival time reached 8.5 years for the treated cohort, nearly doubling the 4.9-year median survival observed in the untreated control group.[1][5]
The survival benefit remained consistent regardless of whether patients were concurrently taking miglustat, an off-label therapy frequently used to manage NPC symptoms. The data marks the first time a medical intervention has formally demonstrated an ability to extend life in this high-mortality population.[2][5]
Boxed warning for hearing loss
While adrabetadex alters the disease's fatal trajectory, its administration carries severe auditory risks. The FDA attached a boxed warning to the medication detailing the potential for permanent hearing impairment, which has ranged from mild deficits to profound hearing loss in clinical trial participants.[1][3]
The auditory damage has occurred even in patients who entered the treatment program with entirely normal baseline hearing. Regulators noted that it remains unknown whether continuing the therapy or lowering the dosage alters the risk of further hearing deterioration once it begins.[2][3]
To manage this risk, the prescribing protocol mandates a comprehensive audiology evaluation before initiating treatment. Patients must undergo pure tone audiometry, speech recognition, and tympanometry testing at baseline, followed by repeated evaluations one to two weeks after each dose to guide ongoing titration.[2][3]
Beyond hearing loss, the most common adverse reactions reported during clinical testing included ataxia, fatigue, vomiting, back pain, and headache. Clinicians are advised that problems with balance and coordination frequently emerge in the days immediately following the intrathecal injection.[1][3]
A decade-long development path
The approval of adrabetadex concludes a turbulent development history that spans more than ten years and multiple corporate acquisitions. Government scientists at the National Institutes of Health initially designed and tested the cyclodextrin molecule before licensing it to the biotechnology sector.[4]
During an NIH-led phase 1/2a trial, 14 participants aged 4 to 23 years received monthly intrathecal infusions for up to 18 months. That early study demonstrated that the cyclodextrin therapy could slow neurological progression compared to a natural history cohort, though it also first identified the hearing loss risk.[2]
The asset was first acquired by Vtesse, which was subsequently bought by Sucampo Pharmaceuticals in 2017. Mallinckrodt Pharmaceuticals then purchased Sucampo less than a year later, advancing the drug into late-stage trials before abruptly halting its clinical development program in 2021.[4]
When Mallinckrodt paused the program, families relying on the experimental infusions faced immense uncertainty. Beren Therapeutics rescued the molecule later that year, acquiring the rights from Mallinckrodt for a $1 million upfront payment and $2 million in future milestones.[4]
The founder-led company maintained the expanded access program while working with regulators to analyze the accumulated long-term data. “We appreciate the close collaboration with the FDA over the last five years to develop a rigorous approach to evaluating more than a decade of clinical evidence,” said Beren CEO Jason Camm.[4]
Shifting the treatment landscape
Before this regulatory action, the FDA had approved two other therapies for Niemann-Pick disease type C in late 2024: arimoclomol and levacetylleucine. However, neither of those medications has been shown to reduce the risk of death, and both carry restrictions that limit their use in infants.[2][5]
Arimoclomol is restricted to patients two years and older when used alongside miglustat, while levacetylleucine is approved only for patients weighing at least 15 kilograms. Adrabetadex’s clearance for patients weighing just 7 kilograms provides a critical option for the youngest and most severely affected children.[2][5]
Because neurological decline in infantile-onset NPC is irreversible, securing a therapy that can be administered early in the disease course has been a primary goal for patient advocates. The ability to intervene before extensive neuronal damage occurs offers the best chance of preserving motor and cognitive function.[3][4]
The approval grants Beren Therapeutics a Priority Review Voucher, a lucrative regulatory incentive awarded to companies that develop treatments for rare pediatric diseases. These vouchers can be used to expedite the FDA review of a future drug or sold to another pharmaceutical manufacturer.[2][4]
These vouchers can be used to expedite the FDA review of a future drug or sold to another pharmaceutical manufacturer.
With three distinct therapies now approved for Niemann-Pick disease type C since 2024, clinical attention is shifting toward combination regimens. Researchers are beginning to explore whether pairing a cholesterol-mobilizing agent like adrabetadex with medications that target downstream cellular stress could yield synergistic benefits.[2][5]
Key points
- Adrabetadex is approved for patients weighing at least 7 kilograms whose neurological symptoms began before age six.
- The therapy reduced the risk of death by 55 percent compared to matched external controls, extending median survival from 4.9 to 8.5 years.
- Administered via intrathecal injection every two weeks, the drug mobilizes trapped cellular cholesterol to bypass the disease's underlying genetic defect.
- The medication carries a boxed warning for permanent hearing impairment, requiring comprehensive audiology evaluations before and during the treatment course.
What we don’t know
- Whether continuing adrabetadex therapy or lowering the dosage alters the risk of further hearing deterioration once auditory decline begins.
- The long-term synergistic effects of combining adrabetadex with other recently approved NPC medications like arimoclomol or levacetylleucine.
- The exact list price Beren Therapeutics will set for the therapy and how broadly insurers will cover the specialized intrathecal administration.
How we got here
Pre-2017
Government scientists at the NIH design and conduct early testing on the cyclodextrin molecule before licensing it to Vtesse.
2017-2018
Sucampo Pharmaceuticals acquires Vtesse, and is subsequently purchased by Mallinckrodt Pharmaceuticals less than a year later.
2021
Mallinckrodt halts the drug's clinical development program; Beren Therapeutics acquires the asset to continue the expanded access program.
September 2024
The FDA approves arimoclomol and levacetylleucine for NPC, though neither demonstrates a survival benefit.
November 17, 2026
The FDA officially approves adrabetadex to reduce the risk of death in infantile-onset NPC.
- Clinical Investigators
- Focus on the unprecedented survival benefit and the importance of early intervention to preserve neurological function.
- Regulatory Authorities
- Emphasize the necessity of strict auditory monitoring to balance the drug's life-extending benefits against the risk of permanent hearing loss.
- Drug Developers
- Highlight the collaborative effort required to rescue the molecule and validate a decade of complex, externally controlled clinical data.
Perspectives this story doesn't cover
- Families of patients who experienced severe hearing loss during trials
- Health insurance providers evaluating coverage for the new therapy
Sources
[1]FDARegulatory AuthoritiesFDA Approves First Drug Shown to Help Patients with Infantile-Onset Niemann-Pick Disease Type C Live Longer
Read on FDA →
[2]NeurologyLiveClinical InvestigatorsFDA Approves Adrabetadex as First Therapy Shown to Improve Survival in Infantile-Onset Niemann-Pick Disease Type C
Read on NeurologyLive →
[3]Contemporary PediatricsClinical InvestigatorsFDA approves adrabetadex for infantile-onset Niemann-Pick type C
Read on Contemporary Pediatrics →
[4]Endpoints NewsDrug DevelopersA molecule designed by government scientists more than a decade ago has won FDA approval to treat infantile-onset Niemann-Pick disease type C
Read on Endpoints News →
[5]Pharmacy TimesDrug DevelopersAdrabetadex Becomes First Therapy Shown to Extend Survival in Infantile-Onset Niemann-Pick Disease Type C
Read on Pharmacy Times →
More in Health
See all →Neuroimmune Modulation
Neuroimmune Modulation Delivers Two-Year Sustained Relief in Advanced Rheumatoid Arthritis
5 sources
Cancer Therapy
Britain's NICE Recommends Padcev and Keytruda Combination for Advanced Bladder Cancer
5 sources
Radiopharmaceuticals
Novel Alpha-Emitting Radiopharmaceutical Shows Strong Tumor Control in Advanced Prostate Cancer
5 sources
Cell Therapy
Artiva Biotherapeutics Shuts Down Autoimmune Cell Therapy Trial and Cuts 94 Percent of Workforce
5 sources
Comments
Every angle. Every day.
Get Health stories with full source coverage and perspective breakdowns, free every day.




